Articles

<i><b>Background:</b></i> COVID-19-related pneumonia was initially rare, though influenza-related pneumonia is well known as a severe complication of influenza. However, COVID-19-related pneumonia may be increasing since the omicron variant of COVID-19 appeared. <i><b>Methods:</b></i> The clinical differences between COVID-19-related and influenza-related pneumonia patients were retrospectively investigated in patients hospitalized from January 2022 to December 2023. <i><b>Results:</b></i><i><b> </b></i>COVID-19-related and influenza-related pneumonias were found in 46 of 285 (15.8%) and 6 of 12 (50.0%) patients, respectively (p<0.001). Their mean ages were 75.5 (45-93) years and 53.8 (19-73) years in COVID-19-related and influenza-related pneumonia cases, respectively (p=0.002). Aspiration pneumonia was more common in COVID-19-related pneumonia (28/46=60.9%) than in influenza-related pneumonia patients, and it was treated by sulbactam/ampicillin (31/46=67.4%). The influenza-related pneumonia patients were more often infected in the work place (2/6=33.3%) and not vaccinated (4/6=66.7%), compared with COVID-19-related patients. Death occurred in 7 of 46 (15.2%) COVID-19 patients, but none of 6 influenza-infected patients died. <i><b>Conclusions:</b></i> These data suggest that COVID-19-related pneumonia presented as aspiration pneumonia in older patients, although influenza-related pneumonia was more common in younger and non-vaccinated patients and might be associated with immune mechanisms during the omicron variant surge era.

Respiratory virus co-infections have been suggested to happen frequently and exacerbate patients’ conditions, but little is known about the detailed rates and the combinations of viruses during the COVID-19 pandemic period. A total of 255 symptomatic patients who underwent multiplex PCR tests were analyzed, and it was found that 6 (6/255=2.4%) patients were infected with multiple viruses. The patients ranged in age from 1 to 38 years, and one female patient was pregnant. Of the 6 patients, 4 had fever, and 5 had human rhinovirus/enterovirus and another virus. These data suggested that the rate of respiratory virus co-infection was low, and the combination of SAS-CoV-2 and other viruses was rare even during the COVID-19 pandemic.

Baloxavir marboxil (BXM) is a novel anti-influenza agent that developed in Japan and inhibit the cap endonuclease specifically, and suggested the more clinical effectiveness in influenza. BXM reduces viral shedding more than do neuraminidase inhibitors (NAIs), and its clinical efficacy is equivalent to that of NAIs but is superior to that of NAIs in the case of type B influenza. BXM does not demonstrate any issues with safety, and treatment with BXM reduces the incidences of complicating sinusitis and bronchitis. Prophylactic administration of BXM inhibits intrafamilial transmission of influenza although low susceptible viruses with a PA/I38X substitution are isolated with a certain frequency following administration of BXM. Finally, In influenza treatment for patients aged 12−19 years and for adult outpatients, BXM can be used with the same recommendation level as oseltamivir.

The pulmonary characteristics of <i>Staphylococcus </i><i>aure</i><i>u</i><i>s</i> (<i>S</i><i>.</i><i> </i><i>aureus</i>) co-infection with respiratory viruses, such as SARS-CoV-2 and influenza virus, are still unclear.<b> </b><b>Case series</b>: Two patients with methicillin-susceptible <i>S</i><i>.</i><i> </i><i>aureus</i><i> </i>(MSSA) infection in the lungs co-infected with either SARS-CoV-2 or influenza virus are reported. Case 1 was a 66-year-old woman who was admitted with SARS-CoV-2 infection. Her chest X-ray and computed tomography (CT) showed multiple cavity formations with infiltration shadows, and MSSA was detected from her sputum and blood, suggesting COVID-19-related bacterial pneumonia and pulmonary embolism. No catheters had been used, but she had skin eruptions and a history of SARS-CoV-2 vaccination. Ampicillin/sulbactam (ABPC/SBT) was administered, and she finally improved. Case 2 was an 87-year-old man with a history of atopic dermatitis who was admitted with moderate pneumonia, and influenza virus co-infection was found. He showed multiple cavitary shadows, and MSSA was isolated from both his sputum and blood. He was diagnosed with influenza-related bacterial pulmonary embolism. No catheters had been used, but he had a history of influenza vaccination. He was also treated by ABPC/SBT and finally improved. <b>Conclusions:</b> These cases suggest that MSSA showed affinity to the lungs when co-infected with either SARS-CoV-2 or influenza virus, and it presented as septic emboli without catheter use. We should consider MSSA infection when patients have SARS-CoV-2 or influenza virus co-infection, and multiple cavity formation and skin disorders are seen, even though they were vaccinated and no catheters were used.

The pandemic of the SARS-CoV2 (COVID-19) that was declared by the World Health Organization (WHO) on 11 March 2020 is still ongoing. One of the early recommendations from CDC and other international agencies is the seasonal influenza vaccination to decrease the effects and burden of COVID-19 pandemic. This review suggests that during COVID-19 pandemic vaccination against seasonal influenza should be conducted all over the year, even for young age groups, because of several reasons. First, the complications of seasonal influenza, especially pneumonia, could increase the burden on the saturated healthcare systems worldwide. Second, the resemblance of symptoms and signs of both seasonal influenza and COVID-19 will difficult diagnosing and isolation of COVID-19 patients. Third, it has been postulated that there is a cross immunity between seasonal influenza and COVID-19.

Avian influenza (bird flu) occurs sporadically in American poultry flocks, decimating these flocks and causing substantial economic losses. Avian influenza also impacts the beliefs of food handlers and preparers in the home (home cooks). Although those who properly handle and prepare processed poultry products cannot succumb to avian influenza, there is a widespread belief that one can contract the bird flu from these foods. Beliefs about getting avian influenza from poultry products and intentions to avoid consuming poultry products are the focus of this study of 285 home cooks. False beliefs about getting avian influenza from handling, preparing, and consuming poultry products are apparent in this sample. Correlational analysis also shows that those holding the false beliefs intend to act upon those beliefs by planning not to consume poultry products. Moreover, the false beliefs about contracting avian influenza from poultry products are correlated with a bias to see oneself as less likely to produce food that contains foodborne diseases. These findings are consistent with, and contribute to, the research literatures on belief formation and change, behavioral intentions, and with research showing how guilt by association thought processes underlie false beliefs related to food safety. This research has important implications for poultry and other food processing industries, and for campaigns to persuade the public about real and imaginary risks associated with particular food products.

It is known that seasonal influenza virus vaccination is important to be taken every year among healthcare workers (HCWs) to avoid transmission of influenza virus and its complications inside the workplace. The reason behind the importance of vaccination is that HCWs are at high risk to be infected with influenza virus. Among the studies addressing the rates of influenza vaccine status among HCWs, a study was conducted in three Middle East countries where the vaccination rates were 24.7%, 67.2%, and 46.4% in United Arab Emirates, Kuwait, and Oman, respectively. Now, after the pandemic of COVID-19 there are beliefs that vaccination with influenza virus could decrease the deaths from COVID-19. A recent retrospective cohort study to detect the effect of seasonal influenza vaccine on the deaths among COVID-19 patients showed that the individuals who didn’t take the influenza vaccine in the last year before being infected with COVID-19 had a higher risk of being hospitalized when compared with patients who took the vaccine. In conclusion, seasonal influenza vaccine could have an important role in the prevention of COVID-19. Seasonal influenza vaccine coverage should be improved among HCWs. New tailored health education programs to improve the attitudes and beliefs of HCWs towards seasonal influenza vaccine during the era of COVID-19 are strongly and urgently needed.

A 16-year-old female patient had influenza and was treated by inhalation of an anti-influenza agent. However, two days later, she showed slight dyspnea, and massive atelectasis of the left lung with hypoxia was found. She was admitted to our hospital (Day 0) and started on antibiotics and steroids, but the atelectasis was worsend on Day 3. Therefore, bronchoscopy was performed on Day 5. After the pus in the left bronchus was removed, the atelectasis was significantly improved. Atelectasis after influenza may be a rare, but critical complication, and bronchoscopy should be considered to release the obstructive lesions.